Published in Cancer Chemother Pharmacol on April 04, 2007
UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol (2009) 1.82
UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. World J Gastroenterol (2012) 1.56
Emerging ethnic differences in lung cancer therapy. Br J Cancer (2008) 1.34
Biomarkers in precision therapy in colorectal cancer. Gastroenterol Rep (Oxf) (2013) 1.15
Pharmacogenetics of irinotecan: An ethnicity-based prediction of irinotecan adverse events. World J Gastrointest Surg (2010) 0.94
The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer. Onco Targets Ther (2015) 0.82
Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms. World J Gastroenterol (2013) 0.81
Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncol (2010) 0.80
Is there diversity among UGT1A1 polymorphism in Japan? World J Gastrointest Oncol (2012) 0.80
Differences in UGT1A1, UGT1A7, and UGT1A9 polymorphisms between Uzbek and Japanese populations. Mol Diagn Ther (2014) 0.78
Genetic variations and haplotype diversity of the UGT1 gene cluster in the Chinese population. PLoS One (2012) 0.77
Pharmacogenetics of solid tumors: directed therapy in breast, lung, and colorectal cancer: a paper from the 2008 william beaumont hospital symposium on molecular pathology. J Mol Diagn (2009) 0.77
A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes. Int J Oncol (2014) 0.76
UGT1A1*6, UGT1A7*3 and UGT1A9*1b polymorphisms are predictive markers for severe toxicity in patients with metastatic gastrointestinal cancer treated with irinotecan-based regimens. Oncol Lett (2016) 0.75
Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol (2005) 2.87
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol (2007) 2.83
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol (2013) 2.45
A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol (2006) 1.81
Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer (2005) 1.58
Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat (2003) 1.54
Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB-IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908. Lung Cancer (2004) 1.48
Dose--volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys (2012) 1.43
Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung. Am J Surg Pathol (2003) 1.35
Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res (2008) 1.34
Predictive markers for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral tongue. Clin Cancer Res (2004) 1.32
Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci (2006) 1.31
Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. Cancer Res (2004) 1.29
Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2010) 1.27
Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys (2003) 1.25
Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci (2008) 1.20
Reasons for permanent tooth extractions in Japan. J Epidemiol (2006) 1.20
Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci (2011) 1.17
Characterization of FDG-PET images after stereotactic body radiation therapy for lung cancer. Radiother Oncol (2010) 1.12
The feasibility study of docetaxel in patients with anaplastic thyroid cancer. Jpn J Clin Oncol (2010) 1.11
Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. Gastric Cancer (2011) 1.08
Risk factors for periodontal disease progression among elderly people. J Clin Periodontol (2002) 1.07
Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung. Lung Cancer (2003) 1.06
Effects of a highly selective acetylcholine-activated K+ channel blocker on experimental atrial fibrillation. Circ Arrhythm Electrophysiol (2010) 1.03
Effect of differences in cancer cells and tumor growth sites on recruiting bone marrow-derived endothelial cells and myofibroblasts in cancer-induced stroma. Int J Cancer (2005) 1.03
Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. Cancer Chemother Pharmacol (2010) 1.02
Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res (2004) 1.02
The role of testosterone in the pathogenesis of prostate cancer. Int J Urol (2008) 1.01
Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci (2011) 1.00
Long-term outcome of human herpesvirus-6 encephalitis after allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2011) 0.99
Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2016) 0.98
FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med (2015) 0.98
Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer (2006) 0.98
Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics (2008) 0.98
Mucinous cystadenoma of the testis. J Urol (2004) 0.97
Role of chemotherapy in treatments for biliary tract cancer. J Hepatobiliary Pancreat Sci (2012) 0.97
Carcinoma coexisting with esophageal leiomyoma. Gastrointest Endosc (2002) 0.96
Prediction of the pathogens that are the cause of pneumonia by the battlefield hypothesis. PLoS One (2011) 0.96
Blockade of paracrine supply of insulin-like growth factors using neutralizing antibodies suppresses the liver metastasis of human colorectal cancers. Clin Cancer Res (2005) 0.95
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clin Cancer Res (2010) 0.95
Influence of visceral obesity on oncologic outcome in patients with renal cell carcinoma. Urol Int (2010) 0.95
CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1. Cancer Sci (2008) 0.94
Geometrical differences in target volumes between slow CT and 4D CT imaging in stereotactic body radiotherapy for lung tumors in the upper and middle lobe. Med Phys (2008) 0.94
Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. Clin Cancer Res (2006) 0.94
A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients. Int J Clin Oncol (2012) 0.94
UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer. Cancer Chemother Pharmacol (2010) 0.93
Measurement of interfraction variations in position and size of target volumes in stereotactic body radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys (2009) 0.93
UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy. Curr Opin Mol Ther (2007) 0.92
Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients. Jpn J Cancer Res (2002) 0.92
Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors. Invest New Drugs (2011) 0.92
Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with bone metastasis. Gastric Cancer (2000) 0.92
Clinical effect of naftopidil on the quality of life of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective study. Int J Urol (2010) 0.91
Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay. Clin Chem (2004) 0.91
Nuclear beta-catenin accumulation as a prognostic factor in Dukes' D human colorectal cancers. Oncol Rep (2004) 0.91
Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer. Cancer Sci (2010) 0.91
Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction. Jpn J Clin Oncol (2008) 0.91
Relationship between dental occlusion and physical fitness in an elderly population. J Gerontol A Biol Sci Med Sci (2002) 0.91
Detailed dosimetric evaluation of intensity-modulated radiation therapy plans created for stage C prostate cancer based on a planning protocol. Int J Clin Oncol (2011) 0.90
Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation. Drug Metab Dispos (2011) 0.90
Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in relation to differentiation of gastric cancer. Int J Cancer (2004) 0.90
Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey. Gastric Cancer (2003) 0.90
Preliminary report of late recurrences, at 5 years or more, after stereotactic body radiation therapy for non-small cell lung cancer. J Thorac Oncol (2012) 0.90
Idiopathic granulomatous gastritis with multiple aphthoid ulcers. Intern Med (2003) 0.90
Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Sci (2008) 0.90
Human adipose-derived stromal/stem cells protect against STZ-induced hyperglycemia: analysis of hASC-derived paracrine effectors. Stem Cells (2014) 0.89
Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors. Cancer Chemother Pharmacol (2014) 0.89
Alterations in hippocampal GAP-43, BDNF, and L1 following sustained cerebral ischemia. Brain Res (2002) 0.89
A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28. Oncology (2012) 0.89